This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) The examples and perspective in this article may not represent a worldwide view of the subject. You may improve this article, discuss the issue on the talk page, or create a new article, as appropriate. (July 2016) (Learn how and when to remove this template message) This article needs to be updated. Please help update this article to reflect recent events or newly available information. (July 2016) (Learn how and when to remove this template message)
Minaprine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • BR: Class C1 (Other controlled substances)[1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life2-2.5 hours
Identifiers
  • 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.043.012 Edit this at Wikidata
Chemical and physical data
FormulaC17H22N4O
Molar mass298.390 g·mol−1
3D model (JSmol)
  • CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3
 ☒NcheckY (what is this?)  (verify)

Minaprine (INN, USAN, BAN; brand names Brantur, Cantor) is a monoamine oxidase inhibitor antidepressant drug[2] that was used in France for the treatment of depression until it was withdrawn from the market in 1996 because it caused convulsions.[3]

A study found that it acts as a reversible inhibitor of MAO-A (RIMA) in rats.[4] It has also been found to weakly inhibit acetylcholinesterase in rat brain (striatum) homogenates.[5]

It has demonstrated significant antibiotic activity against M. chelonae and M. abscessus in tests with antibiotic resistant bacteria.[6]

Minaprine is a member of pyridazines, a secondary amine and a member of morpholines. It has a role as an antidepressant, a serotonin uptake inhibitor, a dopamine uptake inhibitor, a cholinergic drug and an antiparkinson drug.[7]

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ "Minaprine - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2023-12-14.
  3. ^ Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134. S2CID 73036562.
  4. ^ Kan JP, Mouget-Goniot C, Worms P, Biziere K (March 1986). "Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat". Biochemical Pharmacology. 35 (6): 973–978. doi:10.1016/0006-2952(86)90085-7. PMID 3954800.
  5. ^ Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG (February 1999). "Aminopyridazines as acetylcholinesterase inhibitors". Journal of Medicinal Chemistry. 42 (4): 730–741. doi:10.1021/jm981101z. PMID 10052979.
  6. ^ Chopra S, Matsuyama K, Hutson C, Madrid P (July 2011). "Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae". The Journal of Antimicrobial Chemotherapy. 66 (7): 1533–1536. doi:10.1093/jac/dkr154. PMID 21486854.
  7. ^ PubChem. "Minaprine". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-12-14.
Categories